Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

P Ruggenenti, A Perna, G Gherardi, G Garini, C Zoccali… - The Lancet, 1999 - thelancet.com
… in patients with chronic nephropathies and proteinuria of 3 g or more per 24 h, angiotensin-…
In REIN stratum 1, reported here, 24 h proteinuria was 1 g or more but less than 3 g per 24 h…

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

…, E Perticucci, IN Chakarski, D Leonardis, G Garini… - The Lancet, 2005 - thelancet.com
… We tabulated summary statistics by arm and according to proteinuria (<3 g per 24 h or ⩾3
g per 24 h). Risk of progression to end-stage renal disease in the two arms was compared …

Renal involvement in Churg-Strauss syndrome

…, A Pesci, S Monti, G Balestrieri, G Garini… - American journal of …, 2006 - Elsevier
Background: Churg-Strauss syndrome (CSS) is a rare disorder characterized by asthma,
eosinophilia, and systemic vasculitis. Renal involvement is not regarded as a prominent feature…

Evidence of autoimmunity in chronic periaortitis: a prospective study

…, D Corradi, L Manenti, S Ferretti, G Garini… - The American journal of …, 2003 - Elsevier
BACKGROUND: Chronic periaortitis includes idiopathic retroperitoneal fibrosis, inflammatory
aneurysms of the abdominal aorta, and perianeurysmal retroperitoneal fibrosis. It is …

Management of hepatitis C virus-related mixed cryoglobulinemia

F Iannuzzella, A Vaglio, G Garini - The American journal of medicine, 2010 - Elsevier
… and immunosuppressive actions, corticosteroids initially have been used at high oral doses
(eg, prednisone 0.5-1.5 mg/kg/day) or intravenous pulses (methylprednisolone 0.5-1.0 g/day …

HLA–DRB4 as a genetic risk factor for Churg‐Strauss syndrome

…, C Grasselli, A Zanetti, A Pesci, G Garini… - … : Official Journal of …, 2007 - Wiley Online Library
… We evaluated 2 single- nucleotide polymorphisms (SNPs) located in the promoter of the
TNFA gene (TNFA −238A/G and TNFA −308A/G), since they have been demonstrated to …

Ear, nose and throat manifestations of Churg-Strauss syndrome

…, A Vaglio, E Pasanisi, V Vincenti, G Garini… - Acta oto …, 2006 - Taylor & Francis
… All patients with active disease were treated with oral prednisone (1 mg/kg/day) preceded
by an intravenous methylprednisolone bolus of 1 g for three consecutive days, and …

Outcome and prognostic factors during the course of primary small-vessel vasculitides.

…, C Grasselli, E Chierici, U Maggiore, G Garini… - The Journal of …, 2006 - jrheum.org
OBJECTIVE: To identify the prognostic factors of relapse and/or death during the course of
primary small-vessel vasculitides (PSVV), and to differentiate their prognostic relevance by …

Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas

…, P Falzoni, G Monga, G Garini… - Genes …, 1996 - Wiley Online Library
To investigate the molecular mechanisms of tuberous sclerosis (TSC) histopathologic lesions,
we have tested for loss of heterozygosity the two TSC loci (TSC1 and TSC2) and seven …

Cardiac involvement in the Churg-Strauss syndrome

…, G Tirabassi, P Pattoneri, L Pavone, G Garini… - The American journal of …, 2006 - Elsevier
… The treatment of active disease began with an intravenous bolus of methylprednisolone 1
g for 3 days, followed by oral prednisone 1 mg/kg/day. If remission was observed, the dose …